Kimia Biosciences Limited has announced the resignation of Mr. Vipul Goel from his position as Non-Executive Director, effective December 31, 2025. The pharmaceutical company informed the stock exchanges about this board change in compliance with regulatory requirements.

Director Resignation Details

Mr. Vipul Goel has stepped down from his role as Non-Executive Director citing personal reasons for his departure. The company has accepted his resignation and will relieve him from his directorial duties effective December 31, 2025.

The key details of the resignation are presented below:

Regulatory Compliance

The announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Kimia Biosciences has provided all required details as specified under the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

The company secretary and compliance officer, Pallavi Garg (Membership No. A69848), signed the regulatory filing that was submitted to BSE Limited on December 31, 2025. The resignation letter was included as an enclosure with the formal intimation to the stock exchange.

Board Transition

With Mr. Goel's departure, Kimia Biosciences will need to manage the transition in its board composition. The company has completed all necessary formalities related to the resignation and has informed relevant stakeholders about the change in directorial position.

The resignation represents a routine board change driven by personal circumstances rather than any operational or strategic considerations. Kimia Biosciences continues to maintain compliance with all regulatory disclosure requirements regarding changes in its board composition.

Kimia Biosciences Limited has strengthened its board with the appointment of a seasoned pharmaceutical industry veteran. The company announced the appointment of Mr. Kaku Vijaya Shekhar Reddy as Additional Executive Director, bringing over 40 years of pharmaceutical industry experience to the board.

Board Meeting Details

The board meeting was conducted on December 29, 2025, commencing at 7:00 PM and concluding at 8:00 PM. The primary agenda item was the consideration and approval of the directorial appointment under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

New Director Profile and Experience

Mr. Kaku Vijaya Shekhar Reddy (DIN: 00800172) brings substantial industry expertise to the company's leadership team. His appointment details and qualifications are outlined below:

Mr. Reddy is a seasoned pharmaceutical professional with over 40 years of experience in the Active Pharmaceutical Ingredients (API) manufacturing sector. His extensive expertise spans multiple critical areas including operations management, greenfield and brownfield project execution, regulatory compliance, process development, and business strategy.

Leadership Experience and Achievements

Throughout his distinguished career, Mr. Reddy has held several senior leadership positions in reputed pharmaceutical organizations. His previous roles include:

• Managing Director
• Director (Technical)
• Chief Operating Officer
• Vice President – Operations
• General Manager – Operations

He has successfully led multiple large-scale manufacturing projects and has been instrumental in commercializing several API molecules, demonstrating his operational excellence and strategic capabilities in the pharmaceutical sector.

Regulatory Compliance and Independence

The appointment adheres to all regulatory requirements and disclosure norms. Key compliance aspects include:

Shareholder Approval Process

While the board has approved Mr. Reddy's appointment as Additional Executive Director, the appointment remains subject to approval by the company's shareholders. This procedural requirement ensures proper governance and stakeholder participation in key leadership decisions.

The appointment reflects Kimia Biosciences' commitment to strengthening its leadership team with experienced professionals who can contribute to the company's growth and operational excellence in the competitive pharmaceutical industry.